Intramedullary conus medullaris metastasis from prostate carcinoma: A case report and review of the literature

Intramedullary spinal cord metastases (ISCMs) are rare and account for 4-8.5% of central nervous system metastases. Only one case of biopsy-proven ISCM due to prostate cancer has previously been reported. The current study presents an additional unique case of a 74-year-old male who developed sympto...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2014-03, Vol.7 (3), p.717-720
Main Authors: WU, ZENGBAO, XU, SIYI, ZHONG, CHUNLONG, GAO, YANG, LIU, QIANG, ZHENG, YAN, GUO, YANG, WANG, YONG, LUO, QIZHONG, JIANG, JIYAO
Format: Article
Language:English
Subjects:
Androgens
Bladder
Care and treatment
Case reports
Case studies
Catheters
Causes of
Complications and side effects
conus medullaris metastasis
Endocrine therapy
intramedullary spinal cord metastases
Males
Medical prognosis
Metastasis
Mortality
NMR
Nuclear magnetic resonance
Pain
Patients
prognosis
prostate adenocarcinoma
Prostate cancer
Radiation therapy
Surgery
treatment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intramedullary spinal cord metastases (ISCMs) are rare and account for 4-8.5% of central nervous system metastases. Only one case of biopsy-proven ISCM due to prostate cancer has previously been reported. The current study presents an additional unique case of a 74-year-old male who developed symptoms from an intramedullary conus medullaris metastasis as the first manifestation of prostate adenocarcinoma. To the best of our knowledge, this scenario is even more rare and has not previously been reported. The tumor was radically resected, followed by androgen blockade treatment. The patient's neurological deficit significantly improved, with no tumor recurrence during the follow-up period. In addition, the present study provides an overview of the previous literature concerning ISCMs from prostate cancer, and discusses the treatment options.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2014.1808